A new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC

A new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC

Abstract More than 60% of nonsmall cell lung cancer (NSCLC) patients show a positive response to the first ALK inhibitor, crizotinib, which has been used as the standard treatment for newly diagnosed patients with ALK rearrangement. However, most patients inevitably develop crizotinib resistance due...

Full description

Bibliographic Details
Main Authors: Yue Lu, Zhenzhen Fan, Su‐Jie Zhu, Xiaoxing Huang, Zhongji Zhuang, Yunzhan Li, Zhou Deng, Lei Gao, Xuehui Hong, Ting Zhang, Li Li, Xihuan Sun, Wei Huang, Jingfang Zhang, Yan Liu, Baoding Zhang, Jie Jiang, Fu Gui, Zheng Wang, Qiyuan Li, Siyang Song, Xin Huang, Qiao Wu, Lanfen Chen, Dawang Zhou, Jianming Zhang, Cai‐Hong Yun, Liang Chen, Xianming Deng
Format: Article
Language:English
Published: Springer Nature 2022-01-01
Series:EMBO Molecular Medicine
Subjects:
acquired resistance mutations
ALK inhibitor
crizotinib
EML4‐ALK
nonsmall cell lung cancer
Online Access:https://doi.org/10.15252/emmm.202114296

Internet

https://doi.org/10.15252/emmm.202114296

Similar Items